Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.75 USD | -2.86% | -1.45% | -.--% |
May. 29 | BTIG Upgrades Core Scientific to Buy From Neutral, Price Target is $8 | MT |
May. 28 | Cryptoverse: Miners trudge through post-halving world | RE |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- For the past twelve months, EPS forecast has been revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CORZ Stock
- Ratings Core Scientific, Inc.